Akynzeo® (Netupitant/Palonosetron): A Comprehensive Pharmacological and Clinical Review for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

Executive Summary

Netupitant/palonosetron, marketed as Akynzeo®, is a fixed-dose combination antiemetic that represents a significant advancement in the prophylaxis of chemotherapy-induced nausea and vomiting (CINV). This agent uniquely targets two distinct and critical CINV signaling pathways through its dual components: netupitant, a highly selective and long-acting neurokinin-1 (NK1) receptor antagonist, and palonosetron, a second-generation serotonin-3 (5-HT3) receptor antagonist with a distinct pharmacological profile.[1] This dual mechanism provides comprehensive protection against both the acute phase of CINV, primarily mediated by serotonin, and the delayed phase, which is predominantly driven by substance P.

Administered as a single oral capsule or intravenous infusion prior to chemotherapy, Akynzeo® is indicated, in combination with dexamethasone, for the prevention of acute and delayed CINV associated with both highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).[3] Pivotal clinical trials have demonstrated its superior efficacy over palonosetron monotherapy and non-inferiority, with potential advantages in delayed CINV control, when compared to multi-day aprepitant-based regimens.[4] The synergistic interaction and complementary long-acting pharmacokinetic profiles of its components enable sustained antiemetic coverage for up to five days from a single dose, simplifying guideline-recommended prophylaxis and potentially enhancing patient adherence. The safety profile is well-characterized and generally favorable, with the most common adverse events including headache, asthenia, fatigue, and constipation.[3] However, its potent and prolonged inhibition of the cytochrome P450 3A4 (CYP3A4) enzyme by netupitant necessitates careful management of drug-drug interactions, particularly with dexamethasone and certain chemotherapeutic agents.

Introduction and Therapeutic Context

The Pathophysiology of Chemotherapy-Induced Nausea and Vomiting (CINV): Acute vs. Delayed Phases

Chemotherapy-induced nausea and vomiting remains one of the most feared and distressing adverse effects of cancer treatment, profoundly impacting a patient's quality of life, nutritional status, and ability to adhere to prescribed therapeutic regimens.[7] Uncontrolled CINV can lead to serious clinical consequences, including dehydration, electrolyte imbalances, and psychological distress, which may necessitate treatment delays or discontinuations.[8]

The pathophysiology of CINV is complex and biphasic. The acute phase occurs within the first 24 hours following chemotherapy administration and is characterized by a rapid onset of symptoms.[10] The

delayed phase manifests more than 24 hours after treatment and can persist for up to five days, presenting a significant challenge for sustained symptom control.[11] The risk and severity of CINV are influenced by the intrinsic emetogenicity of the chemotherapeutic agents, which are classified into high, moderate, low, and minimal risk categories, as well as patient-specific factors such as gender, age, and history of motion sickness or emesis during pregnancy.[7]

The Role of Serotonin (5-HT3) and Substance P (NK1) Pathways

The distinct temporal phases of CINV are mediated by different neurochemical pathways. The acute phase is primarily driven by the release of serotonin (5-hydroxytryptamine, 5-HT) from damaged enterochromaffin cells in the gastrointestinal (GI) tract.[13] This surge of serotonin activates 5-HT3 receptors located on vagal afferent nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema, initiating the emetic reflex.[15]

Conversely, the delayed phase is largely associated with the activation of neurokinin-1 (NK1) receptors by their endogenous ligand, substance P.[12] Substance P is a neuropeptide found in neurons of the central and peripheral nervous systems, including vagal afferents and key brainstem emetic centers like the nucleus tractus solitarii.[14] Chemotherapy induces the release of substance P, leading to sustained activation of NK1 receptors and the prolonged symptoms characteristic of delayed CINV.[17]

Evolution of Antiemetic Therapy and the Rationale for Dual-Pathway Inhibition

The elucidation of these two distinct pathways has guided the development of targeted antiemetic therapies. The introduction of 5-HT3 receptor antagonists (e.g., ondansetron, granisetron) revolutionized the management of acute CINV but showed limited efficacy in the delayed phase.[7] The subsequent development of NK1 receptor antagonists (e.g., aprepitant) provided a specific mechanism to control delayed emesis, establishing a new standard of care.[7]

Consequently, major clinical practice guidelines, including those from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), recommend a three-drug prophylactic regimen for patients receiving HEC. This regimen consists of a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and a corticosteroid (dexamethasone).[20] While highly effective, these regimens traditionally involved multiple medications administered over several days, such as a three-day course of aprepitant.[22] This complexity can be burdensome for patients already managing the rigors of chemotherapy, creating potential for non-adherence and suboptimal CINV control.[23]

This clinical challenge created a clear rationale for developing a simplified yet equally or more effective prophylactic strategy. The development of Akynzeo® was a direct response to this need. By combining two long-acting agents—the NK1 receptor antagonist netupitant and the second-generation 5-HT3 receptor antagonist palonosetron—into a single fixed-dose formulation, Akynzeo® embodies the principle of guideline-recommended dual-pathway blockade in a single administration. This approach represents a paradigm shift from complex, multi-pill, multi-day regimens to a more convenient, patient-centric, single-dose prophylaxis, designed to provide comprehensive protection throughout the entire five-day period of CINV risk.

Pharmacology of Netupitant and Palonosetron

Mechanism of Action

The therapeutic efficacy of Akynzeo® is derived from the complementary and synergistic actions of its two active components, which target the primary neurochemical pathways of CINV.

Netupitant/Fosnetupitant: A Selective, Long-Acting NK1 Receptor Antagonist

Netupitant is a highly selective antagonist of human substance P/NK1 receptors, with minimal to no affinity for other receptor types, including serotonin, dopamine, or corticosteroid receptors.[12] It functions by competitively binding to and blocking NK1 receptors located in the central nervous system, particularly in the brainstem emetic centers.[18] This action prevents the binding of substance P, which is released in response to chemotherapy, thereby inhibiting the signaling cascade that leads to delayed nausea and vomiting.[14] Positron emission tomography (PET) studies in humans have demonstrated that a single 300 mg oral dose of netupitant achieves high and sustained NK1 receptor occupancy in the brain (≥90% at 6 hours, remaining >75% at 96 hours), providing a durable blockade throughout the delayed CINV risk period.[4]

Fosnetupitant, the component in the intravenous formulation, is a water-soluble phosphorylated prodrug. Following intravenous administration, it is rapidly and completely converted in vivo to its active form, netupitant, by plasma phosphatases.[10] This bioactivation ensures that the IV formulation provides a systemic exposure and pharmacological effect of netupitant that is bioequivalent to the oral dose.[29]

Palonosetron: A Second-Generation 5-HT3 Receptor Antagonist with Unique Pharmacodynamic Properties

Palonosetron is a second-generation 5-HT3 receptor antagonist that is pharmacologically distinct from first-generation agents (e.g., ondansetron, granisetron). It exhibits a significantly higher binding affinity for the 5-HT3 receptor—over 30-fold greater than its predecessors—and a unique molecular interaction profile.[7] Structural and functional studies reveal that palonosetron engages in allosteric binding and demonstrates positive cooperativity, forming a tight and effective wedge in the receptor's binding pocket.[7] This distinct binding mechanism is thought to trigger 5-HT3 receptor internalization, leading to prolonged inhibition of receptor function that outlasts the drug's presence in the plasma.[7] These unique properties are credited with palonosetron's superior efficacy in preventing CINV, particularly its demonstrated activity against delayed emesis, an effect not consistently observed with first-generation 5-HT3 antagonists.[15]

Synergistic Interaction and Dual-Pathway Blockade for Comprehensive CINV Control

The combination of netupitant and palonosetron in a single formulation provides comprehensive, multi-day protection by simultaneously blocking the two primary CINV pathways.[3] Palonosetron targets the serotonin-mediated acute phase, while netupitant targets the substance P-mediated delayed phase, offering coverage for the entire 0- to 120-hour risk period.[20]

Beyond a simple additive effect, preclinical evidence points to a unique synergistic interaction between the two components. Unlike first-generation 5-HT3 antagonists, palonosetron has been shown to inhibit substance P-mediated responses and signaling through the NK1 receptor pathway, demonstrating a form of cross-pathway inhibition.[23] Furthermore, in vitro studies have shown that when combined, netupitant and palonosetron exhibit an enhanced, synergistic inhibition of the substance P response compared to either agent alone.[4] Mechanistic studies also indicate that netupitant-triggered NK1 receptor internalization is significantly enhanced in the presence of palonosetron.[4] This evidence of a true pharmacological synergy at the receptor level provides a strong scientific rationale for the fixed-dose combination and helps explain its robust clinical efficacy.

Pharmacokinetic Profile

The pharmacokinetic profiles of netupitant and palonosetron are remarkably complementary, featuring long elimination half-lives that enable the single-dose, five-day efficacy that is the hallmark of Akynzeo®. This pharmacokinetic harmony was a key consideration in the drug's development, ensuring that both components provide sustained therapeutic concentrations throughout the entire CINV risk period.

Absorption, Distribution, Metabolism, and Excretion (ADME)

Netupitant: Following oral administration, netupitant is absorbed with a time to maximum plasma concentration (Tmax​) of approximately 5 hours.[25] Its oral bioavailability is estimated to be over 60%.[26] Netupitant is highly bound to plasma proteins (>99%) and has a large volume of distribution, indicating extensive partitioning into tissues.[26] Metabolism is the primary route of elimination and is mediated mainly by the CYP3A4 isoenzyme, with minor contributions from CYP2C9 and CYP2D6.[25] This process yields three major pharmacologically active metabolites (designated M1, M2, and M3).[36] Elimination occurs predominantly through the feces (71% to 86% of an administered dose), with negligible renal excretion of the parent drug (<1%), underscoring the importance of hepatic clearance.[26]

Palonosetron: Palonosetron is well absorbed after oral administration, exhibiting an absolute bioavailability of approximately 97%.[34] Similar to netupitant, its

Tmax​ is approximately 5 hours.[34] It is moderately bound to plasma proteins (~62%) and also has a large volume of distribution.[15] Palonosetron is eliminated via multiple pathways, with about 50% cleared through hepatic metabolism and the remainder via renal excretion.[38] Metabolism is mediated by several CYP enzymes, with CYP2D6 playing the primary role, to form two major metabolites that are largely inactive.[37] Approximately 80% to 93% of an administered dose is recovered in the urine, with about 40% as the unchanged parent drug.[37]

Analysis of Long Half-Lives and Implications for Single-Dose Efficacy

A critical and intentionally designed feature of the Akynzeo® combination is the extended elimination half-life of both active components. In cancer patients, netupitant has a mean half-life of approximately 88 hours (and up to 144 hours following IV administration of fosnetupitant), while palonosetron has a half-life of approximately 40 to 58 hours.[3] These durations are substantially longer than those of first-generation antiemetics and the first-in-class NK1 antagonist, aprepitant (half-life of 9 to 13 hours).[26] This sustained systemic exposure is the pharmacokinetic basis for the drug's single-dose administration schedule. It ensures that therapeutic concentrations of both netupitant and palonosetron are maintained, providing continuous NK1 and 5-HT3 receptor blockade throughout the entire five-day period when patients are at risk for both acute and delayed CINV.

Pharmacokinetics of the Intravenous Prodrug Fosnetupitant

The intravenous formulation contains fosnetupitant, a prodrug designed to overcome the poor water solubility of netupitant. Following a 30-minute IV infusion, fosnetupitant is rapidly and completely hydrolyzed by ubiquitous plasma phosphatases to active netupitant.[14] This conversion is so efficient that plasma concentrations of fosnetupitant fall to less than 1% of their peak level within 30 minutes of completing the infusion.[27] The resulting pharmacokinetic profile of netupitant is comparable to that achieved with the oral capsule, ensuring bioequivalence between the two formulations and allowing for consistent efficacy regardless of the route of administration.[27]

Parameter	Netupitant	Palonosetron
Oral Bioavailability	>60% (estimated) 26	~97% 34
Time to Max. Concentration (Tmax​)	~5 hours 25	~5 hours 34
Plasma Protein Binding	>99% 26	~62% 15
Volume of Distribution (Vd​)	Large (~2000 L) 4	Large (~8.3 L/kg) 15
Elimination Half-Life (t1/2​)	~88 hours (Oral) 26; ~144 hours (IV) 4	~40-58 hours 3
Primary Metabolic Pathway	CYP3A4 (>CYP2C9/2D6) 25	CYP2D6 (>CYP3A4/1A2) 37
Primary Excretion Route	Fecal/Hepatic 26	Renal (~40% unchanged) 37

Clinical Efficacy in Pivotal Trials

The clinical development program for Akynzeo® established its efficacy and safety through a series of robust, randomized, double-blind trials. These studies demonstrated the superiority of the fixed-dose combination over its 5-HT3 antagonist component alone and its non-inferiority to another standard-of-care NK1 receptor antagonist regimen.

Prophylaxis in Highly Emetogenic Chemotherapy (HEC)

The pivotal efficacy study in the HEC setting was a Phase II/III trial (NETU 7-07) that compared single-dose oral Akynzeo® plus dexamethasone to oral palonosetron plus dexamethasone in chemotherapy-naïve patients receiving a cisplatin-based regimen (median dose 75 mg/m2).[13] The primary endpoint was the rate of Complete Response (CR), defined as no emetic episodes and no use of rescue medication, during the overall phase (0 to 120 hours post-chemotherapy).[14]

The results demonstrated the statistically significant superiority of Akynzeo®. In the overall phase, 89.6% of patients in the Akynzeo® arm achieved a CR, compared to 76.5% in the palonosetron-only arm (p=0.003).[13] This superiority was consistent across all time points, with Akynzeo® showing significantly higher CR rates in both the acute phase (0-24 hours: 98.5% vs. 89.7%;

p=0.002) and, critically, the delayed phase (25-120 hours: 90.4% vs. 80.1%; p=0.032).[13] Similar significant advantages for Akynzeo® were observed for the secondary endpoints of "no emesis" and "no significant nausea".[27]

Efficacy Endpoint	Akynzeo® (n=135)	Palonosetron 0.5 mg (n=136)	p-value
Complete Response (Overall: 0-120h)	89.6%	76.5%	0.004
Complete Response (Acute: 0-24h)	98.5%	89.7%	0.007
Complete Response (Delayed: 25-120h)	90.4%	80.1%	0.018
No Emesis (Overall: 0-120h)	91.1%	76.5%	0.001
No Significant Nausea (Overall: 0-120h)	89.6%	79.4%	0.021

Prophylaxis in Moderately Emetogenic Chemotherapy (MEC)

A second pivotal Phase III trial (NETU 8-18) evaluated Akynzeo® in 1,450 patients scheduled to receive MEC, specifically anthracycline and cyclophosphamide (AC)-based regimens for breast cancer.[14] This study also compared single-dose oral Akynzeo® plus dexamethasone to oral palonosetron plus dexamethasone. The primary endpoint was CR in the delayed phase.[43]

Akynzeo® again demonstrated superiority. The CR rate in the delayed phase was 76.9% for the Akynzeo® group versus 69.5% for the palonosetron group (p=0.001).[13] The combination was also superior in the overall phase (74.3% vs. 66.6%;

p=0.001) and the acute phase (88.4% vs. 85.0%; p=0.047).[14]

A key feature of this trial was a multi-cycle extension, where patients could continue their assigned treatment for up to seven additional chemotherapy cycles. The results showed that the antiemetic efficacy of Akynzeo® was sustained over multiple cycles, with CR rates remaining consistently higher than those in the palonosetron arm, indicating a lack of tachyphylaxis and durable benefit.[4]

Efficacy Endpoint (Cycle 1)	Akynzeo® (n=724)	Palonosetron 0.5 mg (n=725)	p-value
Complete Response (Delayed: 25-120h)	76.9%	69.5%	0.001
Complete Response (Acute: 0-24h)	88.4%	85.0%	0.047
Complete Response (Overall: 0-120h)	74.3%	66.6%	0.001
No Emesis (Overall: 0-120h)	79.8%	72.1%	<0.001
No Significant Nausea (Delayed: 25-120h)	76.9%	71.3%	0.014

Comparative Efficacy Analysis

To position Akynzeo® within the existing therapeutic landscape, head-to-head trials against the standard-of-care NK1 receptor antagonist, aprepitant, were conducted. A Phase III non-inferiority study in 828 Asian patients receiving HEC compared a single dose of Akynzeo® to a 3-day regimen of aprepitant plus granisetron (APR/GRAN), with both arms receiving dexamethasone.[47] Akynzeo® successfully demonstrated non-inferiority for the primary endpoint of overall CR (73.8% vs. 72.4%).[47]

While individual trials established non-inferiority, a more nuanced picture emerges from pooled analyses. A post-hoc analysis of three similarly designed cisplatin-based trials, encompassing 621 patients on Akynzeo® and 576 on an aprepitant-based regimen, provided deeper insights.[5] While efficacy was similar in the acute phase, Akynzeo® demonstrated a statistically significant advantage over the aprepitant regimen in the delayed phase for CR (81.8% vs. 76.9%;

p<0.05) and for preventing significant nausea.[5] This superior control of delayed symptoms with Akynzeo® is a direct clinical manifestation of its pharmacological properties. The substantially longer half-life of netupitant (~88 hours) compared to aprepitant (~9-13 hours) provides more sustained and potent NK1 receptor blockade during days 3 to 5 post-chemotherapy, the critical window for delayed CINV.[26] This pharmacokinetic advantage translates directly into a measurable clinical benefit, suggesting that while the NK1 receptor antagonist class may be considered equivalent by some guidelines, meaningful differences in duration of action can impact patient outcomes.

Efficacy Endpoint	Akynzeo® (n=621)	Aprepitant Regimen (n=576)	p-value
Complete Response (Acute: 0-24h)	88.4%	89.2%	NS
Complete Response (Delayed: 25-120h)	81.8%	76.9%	<0.05
Complete Response (Overall: 0-120h)	78.4%	75.0%	NS
No Significant Nausea (Overall: 0-120h)	79.5%	74.1%	0.027

Safety and Tolerability Profile

The safety of Akynzeo® has been evaluated in over 1,700 individuals, including healthy subjects and cancer patients, establishing a well-tolerated profile that is generally comparable to that of palonosetron alone.[50] The safety profile of the intravenous formulation was found to be similar to the oral capsule.[3]

Adverse Events in Clinical Trials

In pivotal clinical trials, the most frequently reported adverse reactions (occurring in ≥3% of patients and more commonly than with palonosetron alone) were headache, asthenia (weakness), fatigue, dyspepsia, constipation, and erythema (skin redness).[3] The incidence of these events varied slightly depending on the emetogenicity of the chemotherapy regimen. Multi-cycle safety studies demonstrated that the safety profile remained consistent over repeated administrations, with no evidence of new or cumulative toxicities.[43]

Adverse Reaction	HEC Trial (Cisplatin)	MEC Trial (AC-based)
	Akynzeo® (n=136)	Palonosetron (n=136)
Headache	-	-
Asthenia	-	-
Fatigue	4%	2%
Dyspepsia	4%	2%
Constipation	3%	1%
Erythema	3%	2%

Less common (uncommon) adverse events, affecting up to 1 in 100 people, include alopecia, hypertension, urticaria, dizziness, and insomnia.[52] Rare events, affecting up to 1 in 1,000 people, include back pain, altered mood, acute psychosis, and various electrocardiogram changes such as second-degree atrioventricular block.[27]

Warnings, Precautions, and Contraindications

Despite its favorable safety profile, there are important warnings and contraindications associated with the use of Akynzeo®.

Hypersensitivity Reactions

As Akynzeo® contains palonosetron, there is a risk of hypersensitivity reactions, including anaphylaxis. These reactions have been reported in patients receiving palonosetron, with or without a known prior hypersensitivity to other 5-HT3 receptor antagonists. Patients should be advised to seek immediate medical attention if signs of an allergic reaction occur.[6]

Serotonin Syndrome

A significant and potentially life-threatening risk associated with all 5-HT3 receptor antagonists is Serotonin Syndrome. This condition is caused by an excess of serotonergic activity in the central nervous system and is most likely to occur with concomitant use of other serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), fentanyl, and lithium.[14] Symptoms may include a combination of mental status changes (agitation, hallucinations), autonomic instability (tachycardia, labile blood pressure, hyperthermia), and neuromuscular symptoms (tremor, rigidity, myoclonus).[33] Clinicians must monitor patients for the emergence of these symptoms. If Serotonin Syndrome is suspected, Akynzeo® should be discontinued immediately and supportive care initiated.[14]

Precautions Regarding QT Prolongation and Constipation

While a dedicated thorough QT study did not show any clinically significant effects on ECG parameters, caution should still be exercised when using Akynzeo® in patients with pre-existing risk factors for QT interval prolongation. These include a personal or family history of QT prolongation, electrolyte abnormalities (hypokalemia, hypomagnesemia), congestive heart failure, and concomitant use of other QT-prolonging medications.[27]

Additionally, because palonosetron can increase large bowel transit time, patients with a history of constipation or signs of subacute intestinal obstruction should be monitored closely following administration of Akynzeo®.[27]

Contraindications

Akynzeo® is contraindicated in patients with a known hypersensitivity to netupitant, palonosetron, or any of the excipients.[27] It is also contraindicated during pregnancy due to the potential for fetal harm.[54]

Prescribing Information and Clinical Application

Formulations, Dosage, and Administration

Akynzeo® is available in both oral and intravenous formulations to provide flexibility in clinical practice.

• Oral Formulation: A hard gelatin capsule containing 300 mg of netupitant and 0.5 mg of palonosetron.[1]
• Intravenous (IV) Formulations:
• Lyophilized powder for reconstitution: A single-dose vial containing 235 mg of fosnetupitant (equivalent to 197.5 mg of netupitant) and 0.25 mg of palonosetron.[6]
• Ready-to-use/To-be-diluted solution: A single-dose vial containing 235 mg of fosnetupitant and 0.25 mg of palonosetron in solution.[6]

The recommended dosage is a single dose of Akynzeo® administered prior to each cycle of chemotherapy, in combination with dexamethasone. The specific regimen depends on the emetogenicity of the chemotherapy.

Chemotherapy Emetogenicity	Akynzeo® Dose (Day 1)	Dexamethasone Dosing
Highly Emetogenic (HEC)	One capsule PO 1 hour before chemo OR One vial IV infused over 30 min, starting 30 min before chemo	Day 1: 12 mg PO/IV 30 min before chemo Days 2-4: 8 mg PO/IV once daily
Moderately Emetogenic (MEC)	One capsule PO 1 hour before chemo	Day 1: 12 mg PO 30 min before chemo Days 2-4: None

The oral capsule can be taken with or without food.[58] The IV formulation must be prepared aseptically. The lyophilized powder is reconstituted and then both it and the solution vial must be further diluted in 30 mL of either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP to a final volume of 50 mL.[14] The final solution is administered as an intravenous infusion over 30 minutes.[6] The IV solution is incompatible with any solution containing divalent cations, such as Calcium or Magnesium (e.g., Lactated Ringer's Injection).[33]

Drug-Drug Interactions

The drug interaction profile of Akynzeo® is primarily driven by netupitant's effect on the cytochrome P450 3A4 (CYP3A4) enzyme system. Netupitant is both a substrate and a moderate inhibitor of CYP3A4, and this inhibitory effect can persist for multiple days after a single dose due to its long half-life.[20] This property is a critical clinical consideration, as it can be both beneficial and potentially harmful.

Interactions with CYP3A4 Substrates, Inducers, and Inhibitors

• CYP3A4 Substrates: Akynzeo® can significantly increase the plasma concentrations of co-administered drugs that are metabolized by CYP3A4.[6] This necessitates caution and, in some cases, dose adjustments of the concomitant medication.
• Dexamethasone: This interaction is predictable and clinically managed. Akynzeo® increases the systemic exposure of dexamethasone by more than two-fold.[62] As a result, the dose of dexamethasone must be reduced by approximately 50% when co-administered, which is reflected in the recommended dosing regimens.[27]
• Chemotherapeutic Agents: Caution is required when Akynzeo® is used with chemotherapeutic agents that are CYP3A4 substrates (e.g., docetaxel, etoposide, vincristine, cyclophosphamide) due to the risk of increased toxicity.[27]
• Other Substrates: Increased exposure has also been observed for midazolam and other benzodiazepines.[61]
• CYP3A4 Inducers: Strong CYP3A4 inducers, such as rifampin, can substantially decrease the plasma concentration of netupitant, which may compromise the efficacy of Akynzeo®.[56] Concomitant use with strong inducers should be avoided.[54]
• CYP3A4 Inhibitors: Strong CYP3A4 inhibitors, such as ketoconazole, can increase the systemic exposure to netupitant.[65] However, for a single dose of Akynzeo®, no dosage adjustment is considered necessary.[61]

The potent and long-lasting inhibition of CYP3A4 by netupitant requires careful clinical management. While the interaction with dexamethasone is beneficial and integrated into the dosing schedule, the potential to increase the toxicity of concurrently administered chemotherapy agents with narrow therapeutic windows demands vigilant review of a patient's full medication list before initiating Akynzeo®.

Interacting Agent Class	Example Drug(s)	Effect on Concomitant Drug / Akynzeo®	Clinical Recommendation
CYP3A4 Substrates	Dexamethasone, Midazolam, Docetaxel, Etoposide, Vincristine	Increased plasma concentration of the substrate	Reduce dexamethasone dose by ~50%. Monitor for increased toxicity of other substrates. 27
Strong CYP3A4 Inducers	Rifampin	Decreased plasma concentration of netupitant	Avoid concomitant use. 54
Strong CYP3A4 Inhibitors	Ketoconazole	Increased plasma concentration of netupitant	No dosage adjustment needed for single-dose Akynzeo®. 61
Serotonergic Drugs	SSRIs (e.g., fluoxetine), SNRIs (e.g., venlafaxine), Fentanyl	Increased risk of Serotonin Syndrome	Monitor patient for symptoms of Serotonin Syndrome. 33

Use in Special Populations

Specific recommendations exist for the use of Akynzeo® in certain patient populations:

• Hepatic or Renal Impairment: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh score 5-8) or mild to moderate renal impairment.[56] However, due to a lack of data and potential for increased drug exposure, the use of Akynzeo® should be avoided in patients with severe hepatic impairment (Child-Pugh score ≥9), severe renal impairment (Creatinine Clearance <30 mL/min), or end-stage renal disease.[3]
• Geriatric Patients: While no specific dose adjustments are required based on age, caution is advised when treating patients over 75 years of age due to limited clinical experience in this subgroup and the higher likelihood of comorbidities and decreased organ function.[13]
• Pregnancy and Lactation: Akynzeo® is contraindicated in pregnancy as it may cause fetal harm.[54] It is not known whether netupitant or palonosetron are excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.[13]
• Pediatric Use: The safety and efficacy of Akynzeo® have not been established in pediatric patients (<18 years of age), and its use is not recommended in this population.[13]

Conclusion and Future Directions

Akynzeo® (netupitant/palonosetron) has established itself as a cornerstone of modern antiemetic therapy for the prevention of CINV. Its innovative design as a fixed-dose combination targeting both the 5-HT3 and NK1 receptor pathways provides comprehensive, guideline-concordant prophylaxis in a single oral or intravenous dose. The clinical utility of this approach is firmly supported by robust evidence demonstrating superiority over palonosetron monotherapy and non-inferiority to more complex, multi-day aprepitant-based regimens, with a notable advantage in controlling delayed CINV.

The success of Akynzeo® is rooted in a sophisticated combination of pharmacology and pharmacokinetics. The synergistic interaction between netupitant and the second-generation antagonist palonosetron provides more complete pathway inhibition than either agent could achieve alone. This is complemented by the intentionally matched, long elimination half-lives of both components, which sustain therapeutic drug levels for the entire five-day CINV risk period from a single administration. This simplification of care holds the potential to improve patient adherence and, consequently, clinical outcomes.

While Akynzeo® streamlines dosing, its use demands clinical vigilance. The potent and long-lasting inhibition of CYP3A4 by netupitant is a critical factor in its drug interaction profile, necessitating a mandatory dose reduction of dexamethasone and careful consideration of all concomitant medications, particularly chemotherapeutic agents with narrow therapeutic windows.

Future research should aim to fill existing data gaps. While the oral formulation is indicated for both HEC and MEC, the intravenous formulation's indication is currently limited to HEC; studies confirming its efficacy in MEC, particularly in AC-based regimens, would be valuable.[1] Furthermore, the safety and efficacy in pediatric populations remain unestablished, representing an important area for future investigation to extend the benefits of this effective antiemetic strategy to younger patients undergoing cancer treatment.[13] Overall, Akynzeo® represents a significant therapeutic advance, offering a highly effective, safe, and convenient option that simplifies the management of one of chemotherapy's most challenging side effects.

Works cited

1. Clinical Policy: Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) - Superior HealthPlan, accessed August 26, 2025, https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/CP.PMN.158-03012022.pdf
2. Netupitant/palonosetron - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Netupitant/palonosetron
3. About AKYNZEO® (fosnetupitant/palonosetron) Injection, accessed August 26, 2025, https://www.akynzeo.com/hcp/about-akynzeo
4. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting - PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8463343/
5. Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis - Taylor & Francis Online, accessed August 26, 2025, https://www.tandfonline.com/doi/full/10.2217/fon-2021-0023
6. Akynzeo-USPI.pdf, accessed August 26, 2025, https://www.akynzeo.com/assets/pdf/Akynzeo-USPI.pdf
7. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV) - PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4277122/
8. Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting - Oncology Practice Management, accessed August 26, 2025, https://oncpracticemanagement.com/issues/2015/may-2015-vol-5-no-4/524:akynzeo-netupitant-and-palonosetron-a-dual-acting-oral-agent-approved-by-the-fda-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting
9. 205718Orig1s000 - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000CrossR.pdf
10. Akynzeo (netupitant / palonosetron): Uses, Side Effects, Dosage & Reviews - GoodRx, accessed August 26, 2025, https://www.goodrx.com/akynzeo/what-is
11. An Open-Label, Single-Arm, Multicenter, Observational Study Evaluating the Safety and Effectiveness of Akynzeo® in the Management of Chemotherapy-Induced Nausea and Vomiting in India - PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11024873/
12. Antiemetic Neurokinin-1 Receptor Blockers - StatPearls - NCBI Bookshelf, accessed August 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK470394/
13. Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting - PMC - PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4665070/
14. This label may not be the latest approved by FDA. For current ..., accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210493Orig1s003lbl.pdf
15. Palonosetron: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB00377
16. 5-HT3 receptor antagonists for the treatment of nausea/vomiting - Smith, accessed August 26, 2025, https://apm.amegroups.org/article/view/1037/html
17. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting - Aziz, accessed August 26, 2025, https://apm.amegroups.org/article/view/1033/html
18. Definition of netupitant/palonosetron hydrochloride - NCI Drug Dictionary, accessed August 26, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/netupitant-palonosetron-hydrochloride
19. NK1 receptor antagonist - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/NK1_receptor_antagonist
20. Netupitant/Palonosetron Monograph for Professionals - Drugs.com, accessed August 26, 2025, https://www.drugs.com/monograph/netupitant-palonosetron.html
21. TGA Approves AKYNZEO® (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) - Specialised Therapeutics, accessed August 26, 2025, https://stabiopharma.com/tga-approves-akynzeo-netupitant-palonosetron-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-cinv/
22. Management of acute and delayed chemotherapy- induced nausea and vomiting: role of netupitant– palonosetron combination - ScienceOpen, accessed August 26, 2025, https://www.scienceopen.com/document_file/6252e67a-1f4a-4785-aac2-5056c89d8c63/PubMedCentral/6252e67a-1f4a-4785-aac2-5056c89d8c63.pdf
23. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects | Request PDF - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/publication/225290439_Inhibition_of_substance_P-mediated_responses_in_NG108-15_cells_by_netupitant_and_palonosetron_exhibit_synergistic_effects
24. Akynzeo® (netupitant/palonosetron) as a basis of modern prophylaxis of chemotherapy-induced nausea and vomiting - ResearchGate, accessed August 26, 2025, https://www.researchgate.net/publication/374071329_AkynzeoR_netupitantpalonosetron_as_a_basis_of_modern_prophylaxis_of_chemotherapy-induced_nausea_and_vomiting
25. Netupitant: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 26, 2025, https://go.drugbank.com/drugs/DB09048
26. Netupitant - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Netupitant
27. Akynzeo, INN-netupitant & palonosetron hydrochloride - European ..., accessed August 26, 2025, https://www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_en.pdf
28. 210493Orig1s000 - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210493Orig1s000ChemR.pdf
29. FDA Approves Intravenous Formulation of Akynzeo (fosnetupitant/palonosetron) for Chemotherapy-In, accessed August 26, 2025, https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557834/download-documents?artifactId=LdIz2aTvnfrRu367i9uxqJjxkuqcqVJdz9Hknblspm8wktOWKNp74_c
30. Palonosetron–5-HT3 Receptor Interactions As Shown by a Binding Protein Cocrystal Structure | ACS Chemical Neuroscience - ACS Publications, accessed August 26, 2025, https://pubs.acs.org/doi/10.1021/acschemneuro.6b00132
31. The Antiemetic 5-HT3 Receptor Antagonist Palonosetron Inhibits Substance P-Mediated Responses In Vitro and In Vivo - PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3202469/
32. 80a21073-9072-4b13-95c0-fb422bc5bf85.xml - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/spl/data/80a21073-9072-4b13-95c0-fb422bc5bf85/80a21073-9072-4b13-95c0-fb422bc5bf85.xml
33. AKYNZEO® (fosnetupitant and palonosetron) - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210493s000lbl.pdf
34. Netupitant / Palonosetron (as hydrochloride) - Therapeutic Goods Administration (TGA), accessed August 26, 2025, https://www.tga.gov.au/sites/default/files/auspar-netupitant-161028-pi.docx
35. Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting - PMC - PubMed Central, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6587462/
36. 205718Orig1s000 - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205718Orig1s000ClinPharmR.pdf
37. Palonosetron - Wikipedia, accessed August 26, 2025, https://en.wikipedia.org/wiki/Palonosetron
38. Palonosetron | Davis's Drug Guide for Rehabilitation Professionals, accessed August 26, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139021200
39. What is the mechanism of Palonosetron hydrochloride? - Patsnap Synapse, accessed August 26, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-palonosetron-hydrochloride
40. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/15378559/
41. Single-Dose Netupitant/Palonosetron Bests 3-Day Aprepitant-Based Regimen to Prevent CINV - Targeted Oncology, accessed August 26, 2025, https://www.targetedonc.com/view/single-dose-netupitant-palonosetron-bests-3-day-aprepitant-based-regimen-to-prevent-cinv
42. Akynzeo® (netupitant-palonosetron hydrochloride) Capsules response to PREA Non-Compliance Letter - FDA, accessed August 26, 2025, https://www.fda.gov/media/178142/download
43. Results - Clinical Review Report: Netupitant/Palonosetron 300 mg/0.5 mg (Akynzeo) - NCBI, accessed August 26, 2025, https://www.ncbi.nlm.nih.gov/books/NBK533933/
44. FDA Approves Akynzeo for Chemo-Related Nausea, Vomiting - CancerNetwork, accessed August 26, 2025, https://www.cancernetwork.com/view/fda-approves-akynzeo-chemo-related-nausea-vomiting
45. Efficacy in AC-Treated Patients - Akynzeo, accessed August 26, 2025, https://www.akynzeo.com/hcp/efficacy-in-ac-treated-patients
46. (PDF) Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting, accessed August 26, 2025, https://www.researchgate.net/publication/353412484_NetupitantPalonosetron_A_Review_in_Chemotherapy-Induced_Nausea_and_Vomiting
47. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) - PMC, accessed August 26, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5834144/
48. Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV). - ASCO Publications, accessed August 26, 2025, https://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.10090
49. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/33878896/
50. Demonstrated safety profile in patients receiving chemotherapy - Akynzeo, accessed August 26, 2025, https://www.akynzeo.com/hcp/safety
51. AKYNZEO ® demonstrated safety and efficacy over multiple cycles of chemotherapy, accessed August 26, 2025, https://www.akynzeo.com/hcp/multiple-cycle-study
52. Akynzeo Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 26, 2025, https://www.drugs.com/sfx/akynzeo-side-effects.html
53. Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC) - (emc) | 6993, accessed August 26, 2025, https://www.medicines.org.uk/emc/product/6993/smpc
54. AKYNZEO® Netupitant/Palonosetron Antiemetic Medication, accessed August 26, 2025, https://www.akynzeo.com/hcp/
55. Akynzeo - NPS MedicineWise, accessed August 26, 2025, https://www.nps.org.au/medicine-finder/akynzeo-capsules
56. Akynzeo (netupitant/palonosetron) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 26, 2025, https://reference.medscape.com/drug/akynzeo-netupitant-palonosetron-999963
57. This label may not b - accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210493s004lbl.pdf
58. Netupitant and Palonosetron: MedlinePlus Drug Information, accessed August 26, 2025, https://medlineplus.gov/druginfo/meds/a614053.html
59. www.accessdata.fda.gov, accessed August 26, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205718s002lbl.pdf
60. Akynzeo for Injection (fosnetupitant and palonosetron) FDA Approval History - Drugs.com, accessed August 26, 2025, https://www.drugs.com/history/akynzeo-for-injection.html
61. Drug Interactions with AKYNZEO®, accessed August 26, 2025, https://www.akynzeo.com/hcp/drug-interactions
62. AKYNZEO® Dosing and Administration, accessed August 26, 2025, https://www.akynzeo.com/hcp/dosing-and-administration
63. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data - PubMed, accessed August 26, 2025, https://pubmed.ncbi.nlm.nih.gov/25998320/
64. This medicinal product is subject to additional monitoring. This will allow quick identification of - Akynzeo, INN-netupitant & palonosetron hydrochloride, accessed August 26, 2025, https://ec.europa.eu/health/documents/community-register/2015/20150527131870/anx_131870_en.pdf
65. An evaluation of the drug interaction potential of netupitant with substrates, inhibitor and inducer of CYP3A4. | Journal of Clinical Oncology - ASCO Publications, accessed August 26, 2025, https://ascopubs.org/doi/10.1200/jco.2012.30.15_suppl.e19533
66. AKYNZEO® Injection (IV) Dosing & Administration, accessed August 26, 2025, https://www.akynzeo.com/hcp/akynzeo-iv
67. Netupitant and palonosetron (oral route) - Side effects & dosage - Mayo Clinic, accessed August 26, 2025, https://www.mayoclinic.org/drugs-supplements/netupitant-and-palonosetron-oral-route/description/drg-20122582